Ziprasidone in the Treatment of Borderline Personality Disorder
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
Objective: The aim of this double-blind, placebo-controlled study was to evaluate the
efficacy and tolerability of ziprasidone in the treatment of adult patients with Borderline
Personality Disorder (BPD).
Method: Sixty BPD patients were included in a 12-week, single-center, double-blind,
placebo-controlled study. The subjects were randomly assigned to ziprasidone or placebo in a
1:1 ratio following a two-week baseline period. The Clinical Global Impression scale for use
in BPD patients (CGI-BPD) was the primary outcome measure, and other scales and self-reports
related to affect, behavior, psychosis, general psychopathology domains and clinical safety
were included.
Phase:
Phase 2
Details
Lead Sponsor:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau